Glutaminase activity determines cytotoxicity of l-asparaginases on most leukemia cell lines

Leukemia Research

Volumn 39, Issue 7, 2015, Pages 757-762

  Parmentier, Jean Hugues ^a   Maggi, Maristella ^b   Tarasco, Erika ^b   Scotti, Claudia ^b   Avramis, Vassilios I ^a,c   Mittelman, Steven D ^a,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ALL; Asparaginase; Glutaminase; Leukemia

Indexed keywords

ASPARAGINASE; CYSTEINE; GLUTAMINASE; ISOENZYME; METHIONINE; MUTANT PROTEIN; THREONINE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ESCHERICHIA COLI; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PECTOBACTERIUM CHRYSANTHEMI; PRIORITY JOURNAL; ENZYMOLOGY; LEUKEMIA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ASPARAGINASE; CELL LINE, TUMOR; GLUTAMINASE; HELICOBACTER PYLORI; HUMANS; LEUKEMIA;

EID: 84930378828     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.04.008     Document Type: Article

References (36)

1. Avramis V.I., Tiwari P.N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 2006, 1(3):241-254.
2. Pieters R., Hunger S.P., Boos J., et al. l-Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011, 117(2):238-249.
3. Asselin B.L., Whitin J.C., Coppola D.J., et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993, 11(9):1780-1786.
4. Oettgen H.F., Old L.J., Boyse E.A., et al. Inhibition of leukemias in man by l-asparaginase. Cancer Res 1967, 27(12):2619-2631.
5. Aslanian A.M., Kilberg M.S. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J 2001, 358(Pt 1):59-67.
6. Ding Y., Li Z., Broome J.D. Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines. Leukemia 2005, 19(3):420-426.
7. Fine B.M., Kaspers G.J.L., Ho M., Loonen A.H., Boxer L.M. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005, 65(1):291-299.
8. Abbatiello S.E., Pan Y.-X., Zhou M., et al. Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients. J Proteomics 2008, 71(1):61-70.
9. Balasubramanian M.N., Butterworth E.A., Kilberg M.S. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab 2013, 304(8):E789-E799.
10. Hermanova I., Zaliova M., Trka J., Starkova J. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to l-asparaginase. Exp Hematol 2012, 40(8):657-665.
11. Su N., Pan Y.-X., Zhou M., et al. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 2008, 50(2):274-279.
12. Dimitriou H., Choulaki C., Perdikogianni C., Stiakaki E., Kalmanti M. Expression levels of ASNS in mesenchymal stromal cells in childhood acute lymphoblastic leukemia. Int J Hematol 2014, 99(3):305-310.
13. Appel I.M., den Boer M.L., Meijerink J.P.P., et al. Up-regulation of asparagine synthetase expression is not linked to the clinical response l-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006, 107(11):4244-4249.
14. Kitoh T., Kubota M., Takimoto T., et al. Metabolic basis for differential glutamine requirements of human leukemia cell lines. J Cell Physiol 1990, 143(1):150-153.
15. Le A., Lane A.N., Hamaker M., et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012, 15(1):110-121.
16. Newsholme P. Why is l-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection?. J Nutr 2001, 131(Suppl. 9):2515S-2522S. discussion 2523S-4S.
17. Richards N.G.J., Kilberg M.S. Asparagine synthetase chemotherapy. Annu Rev Biochem 2006, 75:629-654.
18. Willems L., Jacque N., Jacquel A., et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013, 122(20):3521-3532.
19. Samudio I., Konopleva M. Asparaginase unveils glutamine-addicted AML. Blood 2013, 122(20):3398-3400.
20. Avramis V.I., Panosyan E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005, 44(4):367-393.
21. Covini D., Tardito S., Bussolati O., et al. Expanding targets for a metabolic therapy of cancer: l-asparaginase. Recent Patents Anticancer Drug Discov 2012, 7(1):4-13.
22. Avramis V.I. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res 2012, 32(7):2423-2437.
23. Reinert R.B., Oberle L.M., Wek S.A., et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to l-asparaginase. J Biol Chem 2006, 281(42):31222-31233.
24. Chan W.K., Lorenzi P.L., Anishkin A., et al. The glutaminase activity of l-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood 2014, 123(23):3596-3606.
25. Ehsanipour E.A., Sheng X., Behan J.W., et al. Adipocytes cause leukemia cell resistance to l-asparaginase via release of glutamine. Cancer Res 2013, 73(10):2998-3006.
26. Fei F., Stoddart S., Groffen J., Heisterkamp N. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. Mol Cancer Ther 2010, 9(5):1318-1327.
27. Cappelletti D., Chiarelli L.R., Pasquetto M.V., et al. Helicobacter pylori l-asparaginase: a promising chemotherapeutic agent. Biochem Biophys Res Commun 2008, 377(4):1222-1226.
28. Maggi M., Chiarelli L.R., Valentini G., Scotti C. Engineering of Helicobacter pylori l-asparaginase: characterization of two functionally distinct groups of mutants. PLOS ONE 2015, 10(2):e0117025.
29. Distasio J.A., Niederman R.A., Kafkewitz D., Goodman D. Purification and characterization of l-asparaginase with anti-lymphoma activity from Vibrio succinogenes. J Biol Chem 1976, 251(22):6929-6933.
30. Warrell R.P., Arlin Z.A., Gee T.S., et al. Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia. Cancer Treat Rep 1982, 66(7):1479-1485.
31. Mok E., Hankard R. Glutamine supplementation in sick children: is it beneficial?. J Nutr Metab 2011, 2011.
32. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35(8):427-433.
33. Purwaha P., Lorenzi P.L., Silva L.P., Hawke D.H., Weinstein J.N. Targeted metabolomic analysis of amino acid response to l-asparaginase in adherent cells. Metabolomics 2014, 1-11.
34. Iwamoto S., Mihara K., Downing J.R., Pui C.-H., Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007, 117(4):1049-1057.
35. Offman M.N., Krol M., Patel N., et al. Rational engineering of l-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 2011, 117(5):1614-1621.
36. Zweidler-McKay P.A. Clone wars: IgH subclones in preB-ALL. Blood 2012, 120(22):4280-4281.